Abstract 3731
Background
The CYP1A1 gene is located on chromosome 15 (15q22-q24.1) and is part of the cytochrome P450 family. This catabolizing enzyme has an important role in the activation / deactivation of various chemical agents, including xenobiotics and sex hormones. It is related to the synthesis of cholesterol and steroids, and to the metabolism of drugs, coffee, or different metabolites such as those of tobacco. It is found mainly in extrahepatic tissues such as lung, breast or ovarian follicles, and participates in the metabolism of a large number of xenobiotics as well as one of endogenous substrates. Human cytochrome P450 1A 1 is one of the most important enzymes involved in the human carcinogenesis because it metabolizes several procarcinogens to active carcinogens. There are previous studies that have linked rs2470893 with ovarian cancer. Our aim has been to estimate the association between polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in a Mediterranean population.
Methods
We have carried out an observational study at baseline and longitudinally in the PREDIMED-Valencia study including 696 women at high cardiovascular risk. We prospectively analyzed cancer incidence as a secondary outcome in this study. Lifestyle, clinical and biochemical variables were assessed by standardized methods. DNA was isolated from blood and the selected polymorphisms were determined
Results
We detected 8 new cases of ovarian and endometrial cancer from 2003 to 2014, representing 0.6% and 0.1% respectively, of all cancers. In our study it was observed that the variant rs2470893 was related to ovarian and endometrial cancer. The allelic frequency of the A allele was 0.246. The carriers of the G allele were grouped in front of the AA carriers. When assessing the risk of having suffered from ovarian or endometrial cancer according to the genotype of this variant, it was observed that the individuals carrying the AA allele presented a higher risk OR = 8.7: CI 95% (2.4-31.9); P = 0.001 after adjustment for age, intervention group, tobacco smoking and obesity (BMI ≥ 30 Kg/m2).
Conclusions
rs2470893of the CYP1A1 gene could be associated with ovarian and endometrial cancer in a high cardiovascular risk population.
Clinical trial identification
ISRCTN35739639.
Legal entity responsible for the study
University of Valencia.
Funding
Instituto de Salud Carlos III.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4867 - The Combination of TAS-102 and Bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)
Presenter: Hirohiko Kamiyama
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract